AALLOX
ALLOX is a Barcelona-based techbio spin-off from the Centre for Genomic Regulation (CRG) that combines high-throughput experimental genetics, AI, and biophysical energy models to systematically discover allosteric drug-target sites on proteins previously considered 'undruggable.' Founded in 2023, it aims to accelerate therapeutics for diseases such as cancer by mapping how mutations affect protein regulation. It closed an undisclosed pre-seed round in 2023 backed by Asabys Partners, Artá Capital, and Spain's CDTI innovation agency.
SectorsBiotechnology, Drug Discovery, Computational Biology, AI/Machine Learning
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
A
André Faure
CTO & Co-founder
B
Ben Lehner
Chief Scientific Advisor & Co-founder
J
Júlia Domingo
CEO & Co-founder
P
Pablo Baeza Centurión
Chief Discovery Officer & Co-founder
Global models 5
XXaira Therapeutics
United States · xaira.com ↗
Uses generative AI and large-scale experimental data to design proteins/therapeutics, the same 'AI + biology platform for drug discovery' model as ALLOX but at massive scale.
$1.1BComparable
IInsitro
United States · insitro.com ↗
Combines machine learning with high-throughput functional genomics to identify drug targets, closely mirroring ALLOX's genetics+AI target-discovery approach.
$743MComparable
IIsomorphic Labs
United Kingdom · www.isomorphiclabs.com ↗
AI-first drug discovery company modeling protein structure/function to find novel drug targets, similar computational-biology-driven discovery model.
$600MComparable
RRecursion Pharmaceuticals
United States · www.recursion.com ↗
Built a large-scale AI/ML platform mapping biology to find drug targets and candidates, the same data-driven target-discovery thesis as ALLOX.
$500M+Comparable
EExscientia
United Kingdom · www.exscientia.ai ↗
AI-designed drug discovery platform pairing computational models with experimental biology, directly comparable to ALLOX's platform approach (now merged into Recursion).
$500M+Comparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 4
Open as list →
Funding rounds 3
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-10-29 | Seed | €9.4M |
Asabys Partners (Sabadell Asabys II)
+2 more
|
| 2024-09-12 | Seed | €1.8M partial: only one investor's ticket was disclosed |
Lead not disclosed
+2 more
|
| 2023-11-30 | Pre-seed | — | Asabys Partners |
News 7
Open as list →| Published | Article |
|---|---|
| 2026-11-02 |
Dealflow #533: Gameto (Varsavsky) $1.4B deal. Lightspeed's 3rd investment in Spain (XploreAI). Perk expects $450M in revenue this year. ↗
Dealflow.es
2026-11-02+1 source |
| 2026-11-02 |
European tech weekly recap: Over €1.3B invested across 60+ deals ↗
Tech.eu
2026-11-02 |
| 2026-10-29 |
ALLOX capta €9,4 millones en una seed liderada por Asabys, con la participación de CDTI e ICF ↗
Capital-Riesgo.es
2026-10-29 |
| 2025-05-22 |
ALLOX, the startup exploring allosterism to revolutionize drug development ↗
AseBio
2025-05-22 |
| 2025-05-07 |
ALLOX, the startup using allostery to revolutionize drug development ↗
Parc Científic de Barcelona
2025-05-07 |
| 2024-07-03 |
Júlia Domingo, CEO of ALLOX (CRG): "We will generate innovative therapies for currently untreatable diseases" ↗
El·lipse (PRBB)
2024-07-03 |
| 2023-11-30 |
ALLO X, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys ↗
Centre for Genomic Regulation (CRG)
2023-11-30 |